Läkemedelskänslighet, affinitetsproteomik, samt encellsspatiell ytproteomik från patienter med akut myeloisk leukemi vid diagnos Functional and molecular drivers of therapy response in FLT3-mutant leukemia DSRT, affinity proteomics, and single-cell surface spatial proteomics in patient with acute myeloid leukemia at diagnosis 2025-57-1 https://doi.org/10.48723/n3h9-wr71 Swedish National Data Service Svensk nationell datatjänst Landing page Läkemedelskänslighet, affinitetsproteomik, samt encellsspatiell ytproteomik från patienter med akut myeloisk leukemi vid diagnos Functional and molecular drivers of therapy response in FLT3-mutant leukemia DSRT, affinity proteomics, and single-cell surface spatial proteomics in patient with acute myeloid leukemia at diagnosis 2025-57-1 https://doi.org/10.48723/n3h9-wr71 10.1038/s41698-026-01363-8 Erkers, Tom Erkers, Tom Kallioniemi, Olli Kallioniemi, Olli Lehmann, Sören Lehmann, Sören TJ2021-0080 TJ2021-0080 2024-00304, 2020-01091, 2018-02283 2024-00304, 2020-01091, 2018-02283 SB16-0058 SB16-0058 2017-06095 2017-06095 2015.0291 2015.0291 Swedish National Data Service Svensk nationell datatjänst Landing page Precision Medicine Precisionsmedicin Myeloid leukaemia Myeloisk leukemi Specific diseases, disorders and medical conditions Specifika sjukdomar, störningar och medicinska tillstånd The purpose of this study was to investigate the molecular and functional mechanisms underlying resistance to FLT3 inhibitors in FLT3-mutant acute myeloid leukemia, with the goal of identifying predictive markers of response and potential combination strategies to overcome resistance. This repository contains multi-omic data generated on FLT3 mutant and wild-type AML patients. The datasets consist of selective drug sensitivity scores, soluble protein levels, and spatial proteomics data, along with annotation files linking patient IDs across datasets and drug classifications. Data processing methods and software dependencies are specified for each dataset. File List: - sDSS.csv : sDSS table with response to 528 drug perturbations in FLT3 mutant patients. - sDSS_FLT3i.csv : sDSS table with response to 8 FLT3i in FLT3 mutant and wild type patients. - olink_NPX.csv : Soluble protein data table for 17 FLT3 mutant patients. - pixelgen.RData : RData file containing a merged Seurat object with single-cell spatial proteomics data for 6 FLT3 mutant patients. - annotation.csv : Annotation file for all samples. Included is also a list of drug classes: - drug_class.csv Total size of the dataset is approximately 1.4 GB. Detta arkiv innehåller multi-omiska data genererade från patienter med FLT3 mutation och vildtyp AML. Data består av selektiva läkemedelskänslighetsvärden, nivåer av lösliga proteiner samt spatial proteomikdata, tillsammans med annoteringsfiler som länkar patient-ID:n mellan olika dataset och läkemedelsklassificeringar. Databehandlingsmetoder och programvaruberoenden är specificerade för varje dataset. För mer information se beskrivning på engelska. 2018 2021 Sweden Sverige IndividualIndividual IndividIndivid The population consists of 175 acute myeloid leukemia (AML) patients of which 63 have a FLT3 mutation. The proteomic datasets only contain FLT3 mutant patient samples while the drug testing data contains both. Studiepopulationen består av 175 patienter med akut myeloisk leukemi (AML), varav 63 har en FLT3-mutation. Proteomikdatamängderna innehåller endast prover från FLT3-muterade patienter, medan läkemedelstestningsdata omfattar båda grupperna. Numeric Text Other OtherOther ÖvrigtÖvrigt Bone marrow aspirates or peripheral blood were obtained in parallel with clinical routine diagnostics. Mononuclear cells (MNCs) were isolated with lymphoprep. Following MNC isolation, red blood cells were removed with ACK lysis buffer and the cells were directly used for experiments.Bone marrow aspirates or peripheral blood were obtained in parallel with clinical routine diagnostics. Mononuclear cells (MNCs) were isolated with lymphoprep. Following MNC isolation, red blood cells were removed with ACK lysis buffer and the cells were directly used for experiments. Prover från benmärg eller perifert blod togs i samband med rutindiagnostik. Mononukleära celler isolerades genom gradientcentrifugering och röda blodkroppar lyserades med ACK buffert innan analys.Prover från benmärg eller perifert blod togs i samband med rutindiagnostik. Mononukleära celler isolerades genom gradientcentrifugering och röda blodkroppar lyserades med ACK buffert innan analys. Probability: Simple randomProbability: Simple random Sannolikhetsurval: obundet slumpmässigt urvalSannolikhetsurval: obundet slumpmässigt urval Drug sensitivity and resistance testing, FIMM FO5A library, CellTiter GloDrug sensitivity and resistance testing, FIMM FO5A library, CellTiter Glo Drug sensitivity and resistance testing, FIMM FO5A library, CellTiter GloDrug sensitivity and resistance testing, FIMM FO5A library, CellTiter Glo Biological testsBiological tests Biologiska provtagningarBiologiska provtagningar Single cell spatial proteomics kit (Pixelgen, immunology panel I), sequenced using a NovaSeq X Plus systemSingle cell spatial proteomics kit (Pixelgen, immunology panel I), sequenced using a NovaSeq X Plus system Single cell spatial proteomics kit (Pixelgen, immunology panel I), sequenced using a NovaSeq X Plus systemSingle cell spatial proteomics kit (Pixelgen, immunology panel I), sequenced using a NovaSeq X Plus system Biological testsBiological tests Biologiska provtagningarBiologiska provtagningar Olink 96 Immuno-Oncology panel (Olink Proteomics) measured with a BioMarkTM HD System (Fluidigm)Olink 96 Immuno-Oncology panel (Olink Proteomics) measured with a BioMarkTM HD System (Fluidigm) Olink 96 Immuno-Oncology panel (Olink Proteomics) measured with a BioMarkTM HD System (Fluidigm)Olink 96 Immuno-Oncology panel (Olink Proteomics) measured with a BioMarkTM HD System (Fluidigm) Biological testsBiological tests Biologiska provtagningarBiologiska provtagningar Access to data through SND. Access to data is restricted. Åtkomst till data via SND. Tillgång till data är begränsad. restrictedAccess Struyf, N., Gezelius, H., Lundmark, A. et al. Midostaurin response in AML is shaped by a progenitor-like cell state selectively targeted by SMAC mimetics. npj Precis. Onc. (2026). https://doi.org/10.1038/s41698-026-01363-8 Struyf, N., Gezelius, H., Lundmark, A. et al. Midostaurin response in AML is shaped by a progenitor-like cell state selectively targeted by SMAC mimetics. npj Precis. Onc. (2026). https://doi.org/10.1038/s41698-026-01363-8 10.1038/s41698-026-01363-8 2026